Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration PR Newswire Nawigacja wpisu Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference – GlobeNewswire Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Business Wire
